Low-Dose Rivaroxaban to Prevent Recurrences of Venous Thromboembolism in Cancer: A Real-Life Experience with a Focus on Female Patients.

Paolo SantiniCarolina MosoniAlessandro D'ErricoEnrica PorcedduAndrea LupascuEmanuele ValerianiPaolo TondiRoberto PolaAngelo Porfidia

Published in: Journal of clinical medicine (2023)

Low-dose rivaroxaban is potentially effective and safe in cancer patients that require prevention of recurrent VTE. Large-scale studies are needed to confirm these findings.

Keyphrases

venous thromboembolism
low dose
direct oral anticoagulants
end stage renal disease
high dose
ejection fraction
newly diagnosed
chronic kidney disease
atrial fibrillation
pulmonary embolism
papillary thyroid
prognostic factors
peritoneal dialysis
squamous cell carcinoma
case control